SEC Tracker
Get the app

Vaxcyte PCVX

Vaxcyte issues $500M convertible notes

Securities offering

Form
424B5
Filed
Importance
Routine
  1. $500,000,000 aggregate principal amount of 1.50% convertible senior notes due 2032
  2. Underwriters may purchase up to $75,000,000 additional notes for over-allotments
  3. Initial conversion rate of 11.1607 shares per $1,000 principal
  4. Notes mature on October 15, 2032

Written from the 424B5 on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Vaxcyte files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. PERRIGO PRGO public float $3.7B, Jun 27, 2025
  2. Rhythm Pharmaceuticals RYTM public float $3.8B, Jun 30, 2025
  3. Ultragenyx Pharmaceutical RARE public float $3.4B, Jun 30, 2025
  4. Avidity Biosciences RNAM public float $3.4B, Jun 30, 2025
  5. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025